APA (7th ed.) Citation

Egeland, E. V., Seip, K., Skourti, E., Øy, G. F., Pettersen, S. J., Pandya, A. D., . . . Prasmickaite, L. (2024). The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy. British journal of cancer, 131(10), 1656-1667. https://doi.org/10.1038/s41416-024-02875-5

Chicago Style (17th ed.) Citation

Egeland, Eivind Valen, et al. "The SRC-family Serves as a Therapeutic Target in Triple Negative Breast Cancer with Acquired Resistance to Chemotherapy." British Journal of Cancer 131, no. 10 (2024): 1656-1667. https://doi.org/10.1038/s41416-024-02875-5.

MLA (9th ed.) Citation

Egeland, Eivind Valen, et al. "The SRC-family Serves as a Therapeutic Target in Triple Negative Breast Cancer with Acquired Resistance to Chemotherapy." British Journal of Cancer, vol. 131, no. 10, 2024, pp. 1656-1667, https://doi.org/10.1038/s41416-024-02875-5.